Immunothérapie dans le cancer de la vessie : mise à jour 2021 [Immunotherapy for bladder cancer in 2021]

Details

Serval ID
serval:BIB_954186CA59D9
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Immunothérapie dans le cancer de la vessie : mise à jour 2021 [Immunotherapy for bladder cancer in 2021]
Journal
Revue medicale suisse
Author(s)
Cisarovsky C., Latifyan S., Perrinjaquet C., Berthold D., Orcurto A.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
19/05/2021
Peer-reviewed
Oui
Volume
17
Number
739
Pages
974-977
Language
french
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
Intravesical immunotherapy with Calmette-Guerin bacillus (BCG) have been used since decades for the treatment of non-muscle invasive bladder cancer and is a proof of principle that immunotherapy works for this malignancy. Since 2016, immune checkpoint inhibitors (ICI) demonstrated clinical benefits in locally advanced or metastatic bladder cancer, providing potentially durable tumor control in first line therapy or upon relapse after standard treatments. Ongoing clinical trials aim to demonstrate the efficiency of ICI for the treatment of localized disease.
Keywords
Administration, Intravesical, BCG Vaccine, Humans, Immunologic Factors/therapeutic use, Immunotherapy, Neoplasm Recurrence, Local, Urinary Bladder Neoplasms/drug therapy
Pubmed
Create date
31/05/2021 9:54
Last modification date
19/11/2021 7:40
Usage data